| Name | Title | Contact Details |
|---|
Afferent Pharmaceuticals, Inc. is a leader in the development of novel, selective drugs for the treatment of a range of debilitating neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies as well as chronic pain, and who have limited, if any, treatment options. These chronic disorders arise when certain nerve fibers become hyper-sensitized as a result of inflammation, distress, infection or tissue injury, and sometimes remain chronically sensitized for months or even years.
Novocardia is on a mission to transform how cardiovascular disease care is delivered in the United States, and aims to help patients with heart and vascular disease live longer, healthier, and more satisfying lives. We are committed to putting cardiologists, and their patients, at the center of care by investing in our partner practices, deploying purpose-built data and analytics tools to improve patient outcomes, and enabling our partners to transition more successfully to value-based care.
Moran Vista Assisted Living is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
Brighton Health Group is BHPS`s parent company whose approach it is to create an ecosystem in which everyone`s success is contingent upon better health for patients. BHG`s businesses collaborate with physicians, payors and plan sponsors to align the economics with better results, enabling consumers to make better decisions. Combining expertise in healthcare economics with operations drives transformation across the healthcare value chain. BHG aligns financial incentives with quality outcomes and clinical accountability. This formula is building a sustainable business model based on shared rewards between the providers, payors, and health plan sponsors.